A
Alex Pearson
Researcher at Institute of Cancer Research
Publications - 28
Citations - 3196
Alex Pearson is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 16, co-authored 28 publications receiving 2529 citations. Previous affiliations of Alex Pearson include The Royal Marsden NHS Foundation Trust & St Helier Hospital.
Papers
More filters
Journal ArticleDOI
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas C. Turner,Alex Pearson,Rachel Sharpe,Maryou B K Lambros,Felipe C. Geyer,María Ángeles López-García,Rachael Natrajan,Caterina Marchiò,Elizabeth Iorns,Alan Mackay,Cheryl Gillett,Anita Grigoriadis,Andrew Tutt,Jorge S. Reis-Filho,Alan Ashworth +14 more
TL;DR: The data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.
Journal ArticleDOI
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Maria Teresa Herrera-Abreu,Marta Palafox,U. Asghar,Martín A. Rivas,Rosalind J. Cutts,Isaac Garcia-Murillas,Alex Pearson,Marta Guzman,Olga Rodriguez,Judit Grueso,Meritxell Bellet,Javier Cortes,Richard Elliott,Sunil Pancholi,José Baselga,Mitch Dowsett,Lesley-Ann Martin,Nicholas C. Turner,Nicholas C. Turner,Violeta Serra +19 more
TL;DR: It is reported that ER-positive breast cancer cells can adapt quickly to CDK4/6 inhibition and evade cytostasis, in part, via noncanonical cyclin D1-CDK2-mediated S-phase entry, highlighting strategies to prevent the acquisition of therapeutic resistance to these agents.
Journal ArticleDOI
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon,Gaia Schiavon,Sarah Hrebien,Isaac Garcia-Murillas,Rosalind J. Cutts,Alex Pearson,Noelia Tarazona,Kerry Fenwick,Iwanka Kozarewa,Elena Lopez-Knowles,Ricardo Ribas,Ashutosh Nerurkar,Peter Osin,Sarat Chandarlapaty,Lesley-Ann Martin,Mitch Dowsett,Mitch Dowsett,Ian E. Smith,Ian E. Smith,Nicholas C. Turner,Nicholas C. Turner +20 more
TL;DR: ESR1 mutations are rarely acquired during adjuvant AI but are commonly selected by therapy for metastatic disease, providing evidence that mechanisms of resistance to targeted therapy may be substantially different between the treatment of micrometastatic and overt metastatic cancer.
Journal ArticleDOI
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.
Nicholas C. Turner,M B K Lambros,Hugo M. Horlings,Alex Pearson,Rachel Sharpe,Rachael Natrajan,Felipe C. Geyer,M. van Kouwenhove,Bas Kreike,Alan Mackay,Alan Ashworth,M.J. van de Vijver,Jorge S. Reis-Filho +12 more
TL;DR: It is demonstrated that TNBCs are heterogeneous tumours with amplifications of FGFR2 in a subgroup of tumours.
Journal ArticleDOI
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Alex Pearson,Elizabeth C Smyth,Irina S. Babina,Maria Teresa Herrera-Abreu,Noelia Tarazona,Clare Peckitt,Elaine Kilgour,Neil R. Smith,Catherine Geh,Claire Rooney,Ros Cutts,James Campbell,Jian Ning,Kerry Fenwick,Amanda Swain,Gina Brown,Sue Chua,Anne L. Thomas,Stephen R. D. Johnston,Mazhar Ajaz,Katherine Anne Sumpter,Angela Gillbanks,David Watkins,Ian Chau,Sanjay Popat,David Cunningham,Nicholas C. Turner,Nicholas C. Turner +27 more
TL;DR: Using cell lines and patient-derived xenograft models, it is shown that high-level FGFR2 amplification initiates a distinct oncogene addiction phenotype, characterized byFGFR2-mediated transactivation of alternative receptor kinases, bringing PI3K/mTOR signaling under FGFR control.